Clinical Trials and Preclinical Infrastructure Asset Map - Life Sciences

More documents

Recommendations

Info

276 BRITISH COLUMBIA APPENDIX 9. Healthcare Research Centres (cont’d) RESEARCH CENTRE/ URL CONTACT DESCRIPTION 12. RURAL AND ABORIGINAL HEALTH RESEARCH CENTRES Centre for Aboriginal Health Research (CAHR) www.cahr.uvic.ca New Emerging Team for Health in Rural & Northern British Columbia No URL University of Victoria P.O. Box 1700, STN CSC Victoria, B.C. V8W 2Y2 Tel: 250-853-3115 Fax: 250-472-5450 dinarak@uvic.ca CAHR Director: Jeffrey Reading jreading@uvic.ca Tel: 250-472-5451 Fax: 250-472-545 Contact: Chris Lalonde, Associate Director Tel: 250-721-7535 lalonde@uvic.ca NETHRN-BC Department of Geography PO Box 3060 University of Victoria Victoria, B.C. V8W 3R4 Study Director: Aleck Ostry, Canada Research Chair Contact: Analisa Blake, Research Project Manager blakea@uvic.ca CAHR is dedicated to promoting and engaging in health research in partnership with Aboriginal peoples to improve their health. The Centre is a University of Victoria research centre that was created in May 2008, and acknowledge with respect the Coast Salish and Straits Salish peoples on whose traditional territories the Centre is graciously hosted. CAHR is leading Aboriginal population health research, collaborating with the University of Victoria and the University of Northern B.C. on Network Environments for Aboriginal Research B.C. (NEARBC), funded by Michael Smith Foundation for Health Research. CAHR Research projects conducted by the UVic Aboriginal Health Research Group (AHRG) and the CAHR have been in diverse areas of Aboriginal health including: chronic disease, disability, First Nations health, knowledge translation, epidemiology, global indigenous health, participatory and collaborative community-based research, and health disparities. CAHR Research projects include: • Health and mentorship survey of indigenous youth participants at the Cowichan 2008 north American indigenous games • Health practitioners’ perspective on the barriers to diagnosis and treatment of diabetes in aboriginal people on Vancouver island • First nations holistic policy and planning model • First nations regional longitudinal health survey. NETHRN-BC is the acronym for the New Emerging Team for Health in Rural & Northern B.C.. NETHRN-BC aims to develop and enhance research capacity in the social determinants of rural and northern health. NETHRN-BC program is to develop research capacity in the social determinants of rural and northern health in B.C.. This program is multidisciplinary and guided by leading investigators including epidemiologists, geographers, psychologists, sociologists, and statisticians. The program is based at four B.C. universities (University of Victoria, University of Northern B.C., Thompson Rivers University, and UBC). NETHRN-BC researchers are connected to communities and local and regional policy makers concerned about improving the health status of rural and northern British Columbians. NETHRN-BC projects are focused on: • development of rural health services in the Northern Health Authority • early childhood education in the interior Health Authority • exploration of rural/urban differences in health among a cohort of B.C. sawmill workers residing and working in both urban and rural communities throughout the province • exploring the empirical and theoretical dimensions of social capital and its link to health in rural communities in B.C..
CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP 277 RESEARCH CENTRE/ URL CONTACT DESCRIPTION 13. OTHER HEALTH RESEARCH CENTRES Centre for Blood Research (CBR) www.cbr.ubc.ca Centre for Molecular Medicine and Therapeutics www.cmmt.ubc.ca Centre for Translational and Applied Genomics (CTAG) PHSA www.phsa.ca/AgenciesAndServices/ Services/PHSA-Labs/ About-PHSA-Labs/ CTAG.htm 4th Floor, Life Sciences Centre 2350 Health Sciences Mall Vancouver, B.C. V6T 1Z3 Director: Ed Conway Tel: 604-822-4252 Fax: 604-822-7742 director@cbr.ubc.ca 950 West 28th Avenue Vancouver, B.C. V5Z 4H4 Tel: 604-875-3800 Fax: 604-875-3819 info@cmmt.ubc.ca Contact: Nicki Kahnamoui, Director of Business Development Tel: 604-875-2345 x 4832 nicki@cmmt.ubc.ca 3rd floor, 600 West 10th Avenue Vancouver B.C., V5Z 4E6 Tel: 604-877-6000 x 2301 Medical Director: Dr. David Huntsman dhuntsma@bccancer.bc.ca Business Manager: Alicja Parker aparker@bccancer.bc.ca Centre for Blood Research (CBR) was established in 2002 and is currently the largest inter-disciplinary blood research centre in the world. Current membership involves 42 investigators from the Faculties of Applied Science, Arts, Dentistry, Medicine, Pharmaceutical Sciences and Science, and some with appointments at the University of Victoria and the University of Northern B.C.. CBR provides leading edge biomedical research, training, education, and innovative technologies for accelerated delivery of affordable, safe, high-quality diagnostics, therapeutics and medical care. CBR specific areas of interest include: • applying emerging biotechnologies to the study of blood and blood processing for the creation of new knowledge in transfusion science • developing safer means of removing excess iron from blood • identifying risk factors, biomarkers and therapies for innate immune, inflammatory, malignant, hemostatic and thrombotic disorders • developing novel approaches to repair vascular system abnormalities; designing microbe-resistant drugs for a range of viruses, parasites and bacteria • restoring organ function with stem cell technologies • modulating the immune system for better management of chronic inflammatory diseases • improving drug production technologies • establishing integrated research and clinical training programs to better manage the significant medical problems that confront our society. CMMT is focused on exploring the genetic basis of disease and translating this knowledge into new treatment strategies for common and neglected diseases. CMMT works in the fields of developmental biology, neurobiology, lipid biology, bioinformatics, pharmacogenomics, epigenetics, and transgenics. It is a leader in Huntingdon’s disease research and the development of biomarkers to identify adverse drug reactions (ADRs). The Canadian Pharmacogenomics Network for Drug Safety, operated in conjunction with Pharmaceutical Outcomes and Policy Innovations, Children’s and Women’s Health Centre of B.C. (see below), is a nation-wide program that aims to identify genetic markers that are predictive of severe ADRs and implement these in cost-effective diagnostic screening programs to reduce the occurrence of permanent disability and deaths from severe ADRs. CMMT is part of the UBC Faculty of Medicine and is located at the Child and Family Research Institute (CFRI) (see above). CTAG is a genomics and molecular pathology core facility supported by a world class team of molecular pathologists. Its mission is to develop novel laboratory tests to improve the management of a diverse spectrum of disorders including cancer, infectious diseases, and inherited syndromes. CTAG operates at PHSA agencies including the B.C. Cancer Agency, B.C. Centre for Disease Control, B.C. Children’s Hospital and B.C. Women’s Hospital & Health Centre. CTAG offers a broad range of analytical services to the public and private sectors.
Page 1:
M A G N E T I C 12 0 40 33 0 34 0 3
Page 4 and 5:
ii BRITISH COLUMBIA
Page 6 and 7:
2 BRITISH COLUMBIA EXECUTIVE SUMMAR
Page 8 and 9:
4 BRITISH COLUMBIA INTRODUCTION Wit
Page 10 and 11:
6 BRITISH COLUMBIA TABLE 1. Health
Page 12 and 13:
8 BRITISH COLUMBIA FIGURE 2. Clinic
Page 14 and 15:
10 BRITISH COLUMBIA TABLE 2. Clinic
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
22 BRITISH COLUMBIA Much clinical r
Page 28 and 29:
24 BRITISH COLUMBIA FIGURE 3. Sourc
Page 30 and 31:
26 BRITISH COLUMBIA FIGURE 7. Thera
Page 32 and 33:
28 BRITISH COLUMBIA Clinical Invest
Page 34 and 35:
30 BRITISH COLUMBIA TABLE 6. Patien
Page 36 and 37:
32 BRITISH COLUMBIA FIGURE 13. Prov
Page 38 and 39:
34 BRITISH COLUMBIA TABLE 9. Health
Page 40 and 41:
36 BRITISH COLUMBIA TABLE 10. Epide
Page 42 and 43:
38 BRITISH COLUMBIA TABLE 12. Provi
Page 44 and 45:
40 BRITISH COLUMBIA TABLE 13. Examp
Page 46 and 47:
42 BRITISH COLUMBIA TABLE 13. Examp
Page 48 and 49:
44 BRITISH COLUMBIA TABLE 14. Indep
Page 50 and 51:
46 BRITISH COLUMBIA COMPARATIVE POS
Page 52 and 53:
48 BRITISH COLUMBIA ACKNOWLEDGEMENT
Page 54 and 55:
50 BRITISH COLUMBIA APPENDIX 1-2 TA
Page 56 and 57:
52 BRITISH COLUMBIA APPENDIX 1. DES
Page 58 and 59:
54 BRITISH COLUMBIA Edward Miller C
Page 60 and 61:
56 BRITISH COLUMBIA Radiation Thera
Page 62 and 63:
58 BRITISH COLUMBIA The Unit has 15
Page 64 and 65:
60 BRITISH COLUMBIA Neonatal Resear
Page 66 and 67:
62 BRITISH COLUMBIA The B.C. Childr
Page 68 and 69:
64 BRITISH COLUMBIA The clinical tr
Page 70 and 71:
66 BRITISH COLUMBIA FRASER HEALTH A
Page 72 and 73:
68 BRITISH COLUMBIA tional therapis
Page 74 and 75:
70 BRITISH COLUMBIA PROVIDENCE HEAL
Page 76 and 77:
72 BRITISH COLUMBIA Quality control
Page 78 and 79:
74 BRITISH COLUMBIA Clinical trials
Page 80 and 81:
76 BRITISH COLUMBIA The facility ha
Page 82 and 83:
78 BRITISH COLUMBIA Staffing of the
Page 84 and 85:
80 BRITISH COLUMBIA Investigators:
Page 86 and 87:
82 BRITISH COLUMBIA Quality control
Page 88 and 89:
84 BRITISH COLUMBIA The Research Gr
Page 90 and 91:
86 BRITISH COLUMBIA Multiple Sclero
Page 92 and 93:
88 BRITISH COLUMBIA Gastroenterolog
Page 94 and 95:
90 BRITISH COLUMBIA Since the Centr
Page 96 and 97:
92 BRITISH COLUMBIA TABLE A1. Provi
Page 98 and 99:
94 BRITISH COLUMBIA FIGURE A9. Cent
Page 100 and 101:
96 BRITISH COLUMBIA The Unit suppor
Page 102 and 103:
98 BRITISH COLUMBIA TABLE A2. CFRI
Page 104 and 105:
100 BRITISH COLUMBIA Quality contro
Page 106 and 107:
102 BRITISH COLUMBIA • Knowledge
Page 108 and 109:
104 BRITISH COLUMBIA Its staffing i
Page 110 and 111:
106 BRITISH COLUMBIA APPENDIX 3. QU
Page 112 and 113:
108 BRITISH COLUMBIA APPENDIX 5. CL
Page 114 and 115:
110 BRITISH COLUMBIA APPENDIX 5. Cl
Page 116 and 117:
112 BRITISH COLUMBIA APPENDIX 6 TAB
Page 118 and 119:
114 BRITISH COLUMBIA 6.1 Clinical T
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231: 226 BRITISH COLUMBIA 6.3 Clinical T
Page 242 and 243: 238 BRITISH COLUMBIA Pediatrics INV
Page 244 and 245: 240 BRITISH COLUMBIA Pediatrics (co
Page 252 and 253: 248 BRITISH COLUMBIA APPENDICES 7-1
Page 254 and 255: 250 BRITISH COLUMBIA TABLE A3. Pati
Page 256 and 257: 252 BRITISH COLUMBIA TABLE A3. Pati
Page 258 and 259: 254 BRITISH COLUMBIA APPENDIX 8. PR
Page 260 and 261: 256 BRITISH COLUMBIA APPENDIX 8. Pr
Page 262 and 263: 258 BRITISH COLUMBIA APPENDIX 9. He
Page 288 and 289: 284 BRITISH COLUMBIA APPENDIX 10. N
Page 290 and 291: 286 BRITISH COLUMBIA Networks In Wh
Page 296 and 297: 292 BRITISH COLUMBIA APPENDIX 11. I
Page 310 and 311: 306 BRITISH COLUMBIA APPENDIX 12. P
Page 316 and 317: 312 BRITISH COLUMBIA B.C. Centre fo
Page 318 and 319: 314 BRITISH COLUMBIA University of
Page 320: 316 BRITISH COLUMBIA
show all

Clinical Trials and Preclinical Infrastructure Asset Map - Life Sciences

Create successful ePaper yourself

Delete template?

Save as template?